Immunogenic composition
The present application discloses an immunogenic composition comprising at least 2 different N. meningitidis capsular saccharides, wherein one or more is/are selected from a first group consisting of MenA, MenC, MenY and MenW which is/are conjugated to a protein carrier(s) wherein the saccharide:protein ratio (w/w) is between 1:2-1:5, and one or more different saccharides is/are selected from a second group consisting of MenA, MenC, MenY and MenW which is/are conjugated to a protein carrier(s) wherein the saccharide:protein ratio (w/w) is between 5:1-1:1.99.
1. An immunogenic composition comprising
(a) N. meningitidis serogroup A capsular saccharide conjugated to a linker by 1-cyano-4-dimethylamino pyridinium tetrafluoroborate chemistry, wherein the linker is conjugated to tetanus toxoid carrier protein by carbodiimide chemistry;
(b) N. meningitidis serogroup C capsular saccharide conjugated to a linker by 1-cyano-4-dimethylamino pyridinium tetrafluoroborate chemistry, wherein the linker is conjugated to tetanus toxoid carrier protein by carbodiimide chemistry;
(c) N. meningitidis serogroup W capsular saccharide directly conjugated to tetanus toxoid carrier protein by 1-cyano-4-dimethylamino pyridinium tetrafluoroborate chemistry; and
(d) N. meningitides serogroup Y capsular saccharide directly conjugated to tetanus toxoid carrier protein by 1-cyano-4-dimethylamino pyridinium tetrafluoroborate chemistry.
2. The immunogenic composition of claim 1 further comprising a N. meningitidis serogroup B outer membrane vesicle preparation or capsular saccharide.
3. The immunogenic composition of claim 1 further comprising H. influenzae b capsular saccharide conjugated to a carrier protein, said carrier protein selected from the group consisting of tetanus toxoid, diphtheria toxoid, cross reactive material 197, fragment C of tetanus toxoid and protein D, wherein the H. influenzae b conjugate is present in a lower dose than the dose of any other bacterial saccharide conjugate.
4. The immunogenic composition of claim 3 , wherein said H. influenzae b capsular saccharide (Hib) is conjugated to tetanus toxoid.
5. A process for making a vaccine comprising the step of mixing the immunogenic composition of claim 1 with a pharmaceutically acceptable excipient.
6. A method of immunizing a human host against disease caused by Neisseria meningitidis infection comprising administering to the host an immunoprotective dose of the immunogenic composition of claim 1 .
7. A method of treating or preventing disease caused by Neisseria meningitidis infection comprising administering to a human patient in need thereof the immunogenic composition of claim 1 .